abs177.txt	tumor	antigen	heterogeneity	limits	success	of	chimeric	antigen	receptor	(car)t-cell	therapies		embryonal	carcinomas	(ec)	and	mixed	testicular	germ	cell	tumors(tgct)	containing	ec		which	are	the	most	aggressive	tgct	subtypes		are	useful	fordissecting	this	issue	as	ecs	express	the	cd30	antigen	but	also	contain	cd30-/dimcells		we	found	that	cd30-redirected	car	t	cells	(cd30	car	t	cells)	exhibitantitumor	activity	in	vitro	against	the	human	ec	cell	lines	tera-1		tera-2		andnccit	and	putative	ec	stem	cells	identified	by	hoechst	dye	staining		cytolyticactivity	of	cd30	car	t	cells	was	complemented	by	their	sustained	proliferationand	proinflammatory	cytokine	production		cd30	car	t	cells	also	demonstratedantitumor	activity	in	an	in	vivo	xenograft	nod/scid/γcnull	(nsg)	mouse	model	ofmetastatic	ec		we	observed	that	cd30	car	t	cells		while	targeting	cd30+	ec	tumorcells	through	the	car	(i	e			antigen-dependent	targeting)		also	eliminatedsurrounding	cd30-	ec	cells	in	an	antigen-independent	manner		via	a	cell-cellcontact-dependent	fas/fasl	interaction		in	addition		ectopic	fas	(cd95)expression	in	cd30+	fas-	ec	was	sufficient	to	improve	cd30	car	t-cell	antitumoractivity		overall		these	data	suggest	that	cd30	car	t	cells	might	be	useful	as	animmunotherapy	for	ecs		additionally		fas/fasl	interaction	between	tumor	cells	andcar	t	cells	can	be	exploited	to	reduce	tumor	escape	due	to	heterogeneous	antigenexpression	or	to	improve	car	t-cell	antitumor	activity		cancer	immunol	res	6(10)		1274-87		©2018	aacr	
